Heart malformation is the most frequent form of human birth defects and heart disease remains the number one killer of adults in the developed world, largely because of the limited regenerative capacity of the heart. Recent advances have provided insights into potential therapies based on multipotent cardiac progenitor cells (CPCs). Such CPCs can be isolated from early embryos or embryonic stem (ES) cells and cultured to differentiate into numerous cardiac cell types[@R4]--[@R12]. For instance, Nkx2.5^+^, Flk1^+^ or Isl1^+^ CPCs purified from embryoid bodies (EBs) can each give rise to cardiomyocyte, endothelial, and smooth muscle lineages[@R7], [@R8], [@R10], [@R12].

*Nkx2.5* is an ancient cardiac gene activated in CPCs of early embryos[@R13]. Nkx2.5^+^ cells and their progeny populate the precardiac mesoderm located dorsal to the cardiac region and the developing heart tube in vivo[@R14]. Isolated Nkx2.5^+^ cells spontaneously differentiate into distinct cardiac cell lineages including cardiomyocytes, smooth muscle cells and endothelial cells in vitro[@R7], [@R12]. These cardiac cell lineages can also be generated from cells expressing Flk1, a marker of the primitive streak in early embryogenesis[@R10] or Isl1, a CPC marker[@R8], [@R15]. All of these CPCs exhibit overlapping expression patterns in precardiac mesodermal cells in vivo[@R8] and have similar differentiation potential in vitro[@R7], [@R8], [@R10], [@R12], suggesting that they comprise a similar CPC population. Although these multipotent CPCs hold great potential for cardiac repair, the mechanisms that regulate their self-renewal, expansion, and differentiation remain elusive.

We, and others, recently reported that canonical Wnt signaling is a critical regulator of Nkx2.5^+^ and Isl1^+^ CPCs and is responsible for their expansion in vivo and in vitro[@R1]--[@R3]. The inactivation of β-Catenin, the transcriptional mediator of canonical Wnt signaling, in precardiac mesoderm resulted in nearly complete loss of Isl1 cells that contribute to the right ventricle[@R2]. Conversely, stabilization of β-Catenin in the same cells led to an expansion in the number of CPCs[@R2] in vivo, while Wnt/β-Catenin signaling promoted the renewal of CPCs isolated from ES cells[@R2], [@R3]. Notch signaling reciprocally affects Wnt signals in many contexts[@R16] and is thought to inhibit cardiac differentiation[@R17], [@R18], although its function within CPCs in vivo is unknown. Ultimately, these and other early signals must be integrated with a network of transcriptional regulators that influence CPCs.

To examine the CPC-autonomous role of Notch1 signaling in vivo, we deleted *Notch1* in precardiac mesodermal progenitors by crossing *Notch1^flox^* mice[@R19] with mice containing *Cre recombinase* in the *Isl1* locus (*Isl1^Cre^*)[@R20], resulting in Cre-mediated recombination in early CPCs by E7.75. The resulting *Notch1*-null embryos failed to populate the developing right ventricle segment, which is derived from Isl1^+^ CPCs ([Fig. 1a--c, g--i](#F1){ref-type="fig"}). Strikingly, the affected Isl1^+^ CPC pool dorsal to the developing heart was expanded with an increased percentage of proliferating cells marked by a phosphohistone H3 (PH3) antibody ([Fig. 1d--f, j--m](#F1){ref-type="fig"}). The accumulation and proliferation of CPCs behind the developing heart was similar to the effect of stabilized *β-Catenin* on CPCs[@R2], although in the latter CPCs also migrated into the heart.

The striking similarity of Notch1 loss-of-function and β-Catenin gain-of-function mutants in CPCs led us to hypothesize that Notch and β-Catenin signaling intersect during CPC fate or expansion decisions. No significant expression changes of genes involved in the Notch signal transduction pathway were observed in β-Catenin stabilized mice (not shown), suggesting it is unlikely that β-Catenin regulates Notch signaling in CPCs. Using an ES cell line with a bacterial artificial chromosome (BAC) containing green fluorescent protein (GFP) in the *Nkx2.5* locus[@R21], we isolated Nkx2.5-GFP^+^ cells by fluorescent-activated cell sorting (FACS). The Nkx2.5-GFP^+^ cells expressed high levels of *Isl1* ([Supp. fig. 1a](#SD1){ref-type="supplementary-material"}), consistent with these cells representing CPCs. We knocked down (KD) Notch1 levels with *Notch1 siRNAs* in Nkx2.5-GFP^+^ CPCs cultured in a monolayer. Endogenous levels of Notch1 were considerably reduced by the *siRNA* transfection, determined by Western blot analysis ([Fig. 1n](#F1){ref-type="fig"}). Consistent with the in vivo data, *Notch1* KD resulted in an increased number of CPCs ([Fig. 1o](#F1){ref-type="fig"}). *Notch1* KD did not affect the levels of total β-Catenin in CPCs ([Fig. 1n](#F1){ref-type="fig"}). However, the levels of dephosphorylated (free) β-Catenin, a form required to mediate Wnt/β-Catenin signaling, were considerably higher in the *Notch1*-KD CPCs ([Fig. 1n](#F1){ref-type="fig"}). Consistent with this, *Notch1*-KD CPCs showed significantly increased levels of Topflash activity, a luciferase-based reporter system for Wnt/β-Catenin signaling ([Fig. 1p](#F1){ref-type="fig"}). Increased levels of nuclear β-Catenin were also observed in the cardiac mesoderm of the Notch1 mutant embryo ([Supp. fig. 1b](#SD1){ref-type="supplementary-material"}). These findings suggest that Notch1 normally represses CPC expansion and negatively regulates the active form of β-Catenin.

To search for genes responsible for CPC expansion in an unbiased manner, we performed gene expression analyses of β-Catenin-stabilized CPCs in vivo. For this analysis, we generated *Rosa^YFP^*; *Isl1^Cre^*; *β-Catenin(ex3)loxP^loxP^* embryos that express *YFP* in descendants of Isl1^+^ progenitors in the cardiac region with stabilized β-Catenin ([Fig. 2a](#F2){ref-type="fig"}). YFP^+^ cells from embryonic (E) day 9.0 embryos, before cardiac dysfunction, were purified by FACS ([Fig. 2b](#F2){ref-type="fig"}) and used for mRNA expression arrays.

Many known targets of canonical Wnt signaling, including components of the Wnt signaling pathway, were upregulated in mutants, supporting the quality of the data set ([Supp. table 1](#SD4){ref-type="supplementary-material"}, [Supp. fig. 1c](#SD1){ref-type="supplementary-material"}). We found that the expression of genes implicated in cell proliferation and differentiation (e.g., *Ndrg1, Bhlhb2*, and *Fgfs*) was highly upregulated (4--11 fold) in mutants ([Supp. table 1](#SD4){ref-type="supplementary-material"}, [Supp. fig. 1c](#SD1){ref-type="supplementary-material"}). Unexpectedly, several genes essential for CPC development, including *Isl1, Myocd, Shh* and *Smyd1* were significantly downregulated in the mutants and this was validated by quantitative real-time PCR (qPCR) ([Fig. 2c, d](#F2){ref-type="fig"}). It was curious that *Isl1* was downregulated upon stabilization of β-Catenin. In agreement with the array analyses, *Isl1* transcripts were barely detectable in CPCs of β-Catenin-stabilized embryos by in situ hybridization ([Fig. 2e, I](#F2){ref-type="fig"}, [Supp. fig. 1d](#SD1){ref-type="supplementary-material"}). *Smyd1* and *Myocd* transcripts were also significantly downregulated in β-Catenin-stabilized embryos, while *Bhlhb2* was upregulated specifically in the *Isl1^Cre^* domain ([Fig. 2f--h, j--l](#F2){ref-type="fig"}, [Supp. fig. 1d](#SD1){ref-type="supplementary-material"}). Consistent with the opposing functions of Notch1 and β-Catenin described above, *Isl1, Myocd, Shh* and *Smyd1* were significantly downregulated and *Bhlhb2* was upregulated in *Notch1* mutant embryos ([Fig. 2d](#F2){ref-type="fig"}, [Supp. fig. 1e](#SD1){ref-type="supplementary-material"}).

Isl1 is a homeodomain-containing factor that is transiently expressed in CPCs prior to their migration into the heart tube, but is extinguished as further migration and differentiation proceed[@R4]. Although Isl1 is intuitively thought to promote CPC expansion based on its temporal expression, we investigated whether Isl1 downregulation mediates the expansion of CPCs observed in embryos with stabilized β-Catenin. To test this possibility, we used the *Isl1^Cre^* line described above which contains an *IRES-Cre* cassette inserted into the exon encoding the second LIM domain of Isl1, resulting in an *Isl1*-null allele[@R20]. The *Isl1^Cre^* mice were bred with *Rosa^YFP^* mice to generate *Isl1^Cre/Cre^*; *Rosa^YFP^* embryos. We quantified the number of YFP^+^ cells at E8.0 (5 somite stage), before *Isl1^Cre^* expression is initiated in neural cells, by FACS. Surprisingly, *Isl1*-null embryos had a significantly higher percentage of YFP^+^ cells than control embryos ([Fig. 3a, b](#F3){ref-type="fig"}). The results suggest that Isl1 negatively regulates the number of CPCs in vivo. The significant increase is unlikely from higher *Cre* expression in *Isl1-null* embryos, since heterozygous *Cre* mice mediate recombination as efficiently as homozygous *Cre* mice.

To determine if Isl1 also negatively regulates expansion of CPCs derived from pluripotent ES cells, we transiently knocked down *Isl1* levels in the *Nkx2.5-GFP* ES cell line by introducing an *Isl1-shRNA* construct, which efficiently reduced *Isl1* transcripts by \~75% ([Supp. fig. 1f](#SD1){ref-type="supplementary-material"}). We then quantified the number of Nkx2.5-GFP^+^ CPCs in EBs from embryoid day (ED) 6 as cardiac progenitors begin to emerge and differentiate from primitive mesoderm[@R7], [@R8]. The KD of *Isl1* from ED0--3 did not change the number of Nkx2.5^+^ progenitors (data not shown). However, the KD of *Isl1* from ED3--6, just after emergence of mesoderm, resulted in an increased cardiac progenitor population at ED6--8 ([Fig. 3c](#F3){ref-type="fig"}, [Supp. fig. 2a](#SD2){ref-type="supplementary-material"}), consistent with our in vivo data.

These findings prompted us to test if Isl1 downregulation was required for CPC expansion induced by β-Catenin. We transfected Nkx2.5-GFP^+^ FACS-purified CPCs from day 5 EBs with a stabilized β-Catenin expression construct[@R22] with or without an *Isl1* expression construct. As previously reported, increased CPC expansion was evident two days after transfection with stabilized β-Catenin ([Fig. 3d](#F3){ref-type="fig"}). However, co-transfection with *Isl1* restored the number of CPCs to normal levels ([Fig. 3d](#F3){ref-type="fig"}). This suggests that the decrease in Isl1 is necessary for Wnt/β-Catenin signaling--mediated expansion of CPCs.

Because Isl1 appeared to be involved in repressing expansion of CPCs, we investigated whether Isl1 promotes differentiation in the ES cell system. We generated a stable *Isl1*-KD ES cell line by introducing an *Isl1 shRNA* construct into *Nkx2.5-GFP* ES cells and clonally isolating cells with effective (\~80%) *Isl1*-KD ([Supp. fig. 1f](#SD1){ref-type="supplementary-material"}). Similar to the transient *Isl1*-KD, the number of Nkx2.5-GFP^+^ cardiac progenitors was significantly increased at ED6 ([Supp. fig. 2b](#SD2){ref-type="supplementary-material"}). However, cells differentiated from the *Isl1*-KD ES cells showed severely reduced beating frequencies with compromised expression of cardiac sarcomeric genes (*Myh6, Myh7, Mlc2a, Mlc2v*) from ED9 ([Fig. 3e, f](#F3){ref-type="fig"}). To determine the CPC-autonomous role of Isl1 during cardiac differentiation, we FACS-purified Nkx2.5-GFP^+^ CPCs from ED5 EBs and differentiated them by re-aggregating in suspension ([Fig. 3g](#F3){ref-type="fig"}). Nkx2.5-GFP^+^ CPCs are multipotent and differentiate into myocardial, smooth muscle, and endothelial lineages[@R7], [@R12]. Normal levels of endothelial gene expression (CD31, Flk1) were observed in differentiating *Isl1*-KD CPCs ([Fig. 3h](#F3){ref-type="fig"}). However, expression of cardiomyocyte and smooth muscle genes was severely downregulated ([Fig. 3h](#F3){ref-type="fig"}). This suggests that Isl1 not only represses expansion of CPCs, but is also necessary for proper differentiation of CPCs into the myocardial and smooth muscle, but not endothelial, cell lineages.

Given that Isl1 loss-of-function suppressed cardiomyocyte differentiation, we sought to determine if Isl1 conversely plays an instructive role in myocardial lineage formation. *Isl1* expression levels were upregulated from ED4--5 EBs ([Supp. fig. 3a](#SD3){ref-type="supplementary-material"}). To prematurely increase *Isl1* expression levels in a temporally and physiologically relevant way, we transiently transfected an *Isl1* expression construct (30 ng/10^5^ cells) into dissociated ED2 EB cells and re-aggregated them for further differentiation ([Fig. 4a](#F4){ref-type="fig"}). This resulted in about a twofold increase in *Isl1* levels at ED6 ([Fig. 4b](#F4){ref-type="fig"}). Myocardial differentiation was monitored by sarcomeric gene (e.g., *Myh7, Mlc2v, Actc1*) expression over the course of EB differentiation. Sarcomeric gene expression levels did not change during the early phase of CPC differentiation (data not shown). However, by ED8, *Isl1*-transfected EBs expressed higher levels of cardiac muscle genes than control EBs ([Fig. 4c](#F4){ref-type="fig"}). To determine the effect of excess Isl1 on the number of cardiomyocytes, we utilized the *Myh7-GFP* ES cell line to quantify cardiomyocytes. We observed a 25% increase in Myh7^+^ cells in *Isl1*-overexpressed EBs ([Fig. 4d](#F4){ref-type="fig"}, [Supp. fig. 3b](#SD3){ref-type="supplementary-material"}). This suggests that Isl1 can promote myocardial differentiation of CPCs in an instructive manner.

In addition to *Isl1, Myocd* and *Smyd1* are important genes for cardiogenesis[@R23]--[@R27] that were downregulated in CPCs with increased β-Catenin ([Fig. 2c--g, i--k](#F2){ref-type="fig"}). Myocd is a potent coactivator for serum response factor regulation of smooth muscle[@R24] and cardiac gene expression[@R27]. Smyd1 is a muscle-restricted histone methyltransferase essential for cardiomyocyte differentiation in vivo[@R23], [@R25]. To determine whether Isl1 regulates these genes in CPCs, we used Nkx2.5-GFP^+^ CPCs purified from the stable *Isl1*-KD ES cell line. *Smyd1* levels did not change, but *Myocd* levels were significantly reduced in the *Isl1*-KD CPCs ([Fig. 5a](#F5){ref-type="fig"}). To determine if this is also the case in vivo, we performed in situ hybridization for *Myocd* transcripts in *Isl1*-null embryos. In agreement with in vitro data, *Myocd* levels were severely compromised in *Isl1*-null embryos, while *Smyd1* levels did not change ([Fig. 5b--i](#F5){ref-type="fig"}). This suggests that Isl1 is required for normal *Myocd* expression.

Through bioinformatic searches, we identified an Isl1 consensus site in an evolutionarily conserved island (555 bp) located in the first intron of the *Myocd* locus ([Fig. 5j](#F5){ref-type="fig"}). We observed robust transactivation of luciferase when the element was linked to luciferase reporter and introduced into ED6--8 EBs (when endogenous Isl1 is enriched and biologically functional) ([Fig. 5k](#F5){ref-type="fig"}). However, the luciferase activity was significantly reduced when the Isl1 site was mutated ([Fig. 5k](#F5){ref-type="fig"}). In addition, excessive Isl1 further increased luciferase activity with the Isl1 site intact but not with the site mutated ([Fig. 5k](#F5){ref-type="fig"}). Chromatin immunoprecipitation (ChIP) with anti-Isl1 antibodies in ED8 EBs revealed that the site was associated with Isl1 protein ([Fig. 5l](#F5){ref-type="fig"}). This association was further confirmed by electrophoretic mobility shift analyses that showed the specific binding of Isl1 to the site ([Fig. 5m](#F5){ref-type="fig"}). Together, these data suggest that Isl1 may directly regulate *Myocd* expression.

Since Isl1 did not affect *Smyd1* expression, we hypothesized that β-Catenin might activate a transcriptional repressor to downregulate *Smyd1* expression. Among the transcriptional repressors affected by β-Catenin in our array, *Bhlhb2* was the most highly upregulated. Bhlhb2 is a basic helix-loop-helix (bHLH)-containing DNA-binding repressor that is involved in many biological processes, including proliferation, differentiation and regulation of circadian rhythms[@R28]--[@R30]. qPCR confirmed that *Bhlhb2* was highly upregulated in embryos with stabilized β-Catenin ([Fig. 5n](#F5){ref-type="fig"}) consistent with the upregulation by in situ hybridization in the cardiac area and other domains of *Isl1^Cre^* activity ([Fig. 2h, l](#F2){ref-type="fig"}). Overexpression of *Bhlhb2* in Nkx2.5-GFP^+^ CPCs mimicked the Smyd1 repression observed with β-Catenin stabilization ([Fig. 5o](#F5){ref-type="fig"}). *Isl1* expression was not affected by Bhlhb2, providing an important control ([Fig. 5o](#F5){ref-type="fig"}). We identified four conserved Lef/Tcf consensus sites in the 5′ and 3′ UTRs of *Bhlhb2* ([Fig. 5p](#F5){ref-type="fig"}) and tested whether any were directly bound by β-Catenin. ChIP with anti-β-Catenin antibodies in ED8 EBs revealed that two of the four sites (A and D) were indeed associated with β-Catenin ([Fig. 5q](#F5){ref-type="fig"}). To determine which site can mediate Wnt/β-Catenin signaling, conserved elements encompassing the Lef/Tcf sites were individually inserted upstream of luciferase reporter and examined luciferase activity in ED8 EBs. We found that the construct containing site D, but not A, resulted in a significant increase in luciferase activity upon stimulation with β-Catenin or 6-bromoindirubin-3′-oxime (BIO), a Wnt/β-Catenin signaling activator ([Fig. 5r](#F5){ref-type="fig"}). This increase was, however, not observed in cells transfected with a mutant construct ([Fig. 5r](#F5){ref-type="fig"}). These data suggest that Bhlhb2 may be a direct target of the Wnt signal.

Through use of mouse genetics and the embryonic stem cell system, we have shown that Wnt/β-Catenin signaling functions as a central regulator of CPCs by integrating signals from the Notch pathway and regulating a cascade of downstream transcriptional events involving Isl1, Myocd and Smyd1 ([Fig. 5s](#F5){ref-type="fig"}). We found that Notch1 activity within CPCs was required for their exit from the expansive state into the differentiated state, providing the first evidence for Notch signaling requirement within multipotent CPCs in vivo. Consistent with Notch1's negative regulation of active β-Catenin, Notch1 loss-of-function and β-Catenin gain-of-function had similar effects on expression of the cardiac transcription factors, *Isl1, Myocd, Smyd1* and *Bhlhb2*. Our finding that CPCs in vivo and in vitro had greater expansion upon disruption of Isl1 and that Isl1 could promote differentiation suggests that despite its very transient expression, Isl1 triggers the further development of CPCs into cardiac cells rather than promoting its renewal state. Strikingly, Isl1 downregulation induced by β-Catenin was necessary for Wnt/β-Catenin-induced expansion of CPCs. These findings reveal a regulatory network controlling CPC expansion and cell fate that involve unanticipated functions of β-Catenin, Notch1 and Isl1 that may be leveraged for regenerative approaches involving CPCs.

Methods {#S1}
=======

Mouse Genetics and CPC and ES Cell Culture {#S2}
------------------------------------------

The control (*Rosa*^*YFP*/+^; *Isl1*^*Cre*/+^) or mutant (*Rosa*^*YFP*/+^; *Isl1*^*Cre*/+^; *β-Catenin(ex3)loxP*^*loxP*/+^) embryos were obtained by crossing *Rosa*^*YFP*/+^; *β-Catenin(ex3)loxP*^*loxP*/+^ with *Isl1*^*Cre*/+^ mice[@R20], [@R31]. YFP^+^ cells from the resulting embryos were purified by FACS and used for gene expression analyses. To quantify embryonic CPCs, *Rosa*^*YFP*/+^; *Isl1*^*Cre*/+^ were crossed with *Isl1*^*Cre*/+^ mice, and YFP^+^ cells from the resulting embryos were counted by FACS. To generate *Isl1*^*Cre*/+^; *Notch1*^*loxP/loxP*^, *Isl1*^*Cre*/+^; *Notch1*^*loxP*/+^ mice were crossed with *Notch1*^*loxP/loxP*^ mice[@R19]. Genotyping was done as described[@R2]. To identify *Isl1-het* (*Isl1^Cre/+^)* or null (*Isl1^Cre/Cre^*) embryos, DNA was isolated from individual embryos, and qPCR was done using SYBR Green (Applied Biosystems) with control *Isl1* and *Cre* primers shown in [Supp. table 2](#SD4){ref-type="supplementary-material"}. ES cells and purified Nkx2.5-GFP^+^ CPCs were propagated undifferentiated or differentiated as previously described[@R2]. For CPC differentiation, the FACS-purified GFP^+^ cells were re-aggregated in suspension (10^5^ cells per well) in ultra-low-attachment 24-well plates (Corning).

Flow Cytometry and Gene Expression Analysis {#S3}
-------------------------------------------

A Becton Dickinson FACS Diva flow cytometer and cell sorter were used for quantifying and purifying Nkx2.5-GFP^+^ or Myh7-GFP^+^ cells. For the microarray analysis and qPCR, total RNA was amplified with the WT-Ovation Pico RNA Amplification System, fragmented and labeled with the FL-Ovation cDNA Biotin Module V2 (Nugen). The hybridization, staining and scanning of the Affymetrix GeneChips were performed in the Gladstone Genomics Core Lab. Raw data generated from at least three independent experiments were further analyzed by the group of Dr. Ru-Fang Yeh at the Center for Informatics and Molecular Biostatistics, UCSF. To quantify gene expression in *Notch1* mutant embryos, total RNA was isolated from hearts and pharyngeal arches from E10.0 embryos. qPCR was performed with the ABI Prism system (7900HT, Applied Biosystems). TaqMan primers used in this study are listed in [Supp. table 2](#SD4){ref-type="supplementary-material"}. All samples were run at least in triplicate. Real-time PCR data were normalized and standardized with SDS2.2 software.

Constructs, siRNA, Transfection, EMSA and Luciferase Assays {#S4}
-----------------------------------------------------------

For *Isl1*-KD experiments, an *Isl1 shRNA* construct set (RMM4534-NM_021459, Open Biosystems) was used to transiently transfect EBs and to generate stable KD ES cell lines. For *Isl1* or *Bhlhb2* overexpression studies, their full-length cDNAs (Open Biosystems) were amplified and cloned into the *pEF-DEST51* vector (*pDEST51-Isl1* or *Bhlhb2*) through the *pENTR* vector (*pENTR-Isl1* or *Bhlhb2*) using the Gateway system (Invitrogen). *pEF-lacZ* (Invitrogen) was used as a control. For *Notch1*-KD studies, Block-iT Alexa Fluor Red (46--5318, Invitrogen) or *Notch1 siRNA* (M-041110-00-0005, Dharmacon) was used at concentration of 50 or 100 nM. *Myocd-luc* was generated by cloning their corresponding regions into the *pGL3* luciferase vector (Promega). *Myocd-luc^mt^* was generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene). For *Bhlhb2D-luc* and *Bhlhb2D-luc^mt^* generation, oligonucleotides containing the Tcf/Lef site were cloned into the *pGL3* vector. All the oligonucleotide sets are listed in [Supp. table 2](#SD4){ref-type="supplementary-material"}. Stabilized β-Catenin and Top/Fop-flash luciferase constructs were kindly provided by Dr. A. Barth (Stanford University) and the laboratory of Dr. R. Moon (University of Washington), respectively. ES cells, EBs or CPCs were transfected with indicated constructs or siRNA using Lipofectamine 2000 (Invitrogen) after generating single-cell suspension with Accutase (Chemicon). EMSAs and luciferase assays were performed as described previously[@R32], [@R33]. For EMSAs, the pCITE-ISL1[@R34] construct containing the truncated *Isl1* cDNA with the homeodomain was kindly provided by Dr. B. Black (University of California, San Francisco) and used to generate Isl1 protein. All EMSA probes are listed in [Supp. table 2](#SD4){ref-type="supplementary-material"}. For luciferase assays, Renilla was used as an internal normalization control.

In Situ Hybridization, Immunostaining and Western Analysis {#S5}
----------------------------------------------------------

Whole-mount in situ hybridization was performed as described with designated antisense probes[@R4], [@R23], [@R26]. *Bhlhb2* antisense riboprobe was synthesized and purified from *pENTR-Bhlhb2*. To detect proliferating cells in CPCs, embryo sections were stained with anti-Phospho-histone H3 (Upstate) and anti-Isl1 (DSHB). To visualize Isl1 protein in Notch1 mutant embryos, the TSA System (PerkinElmer) was used to amplify Isl1 signals. Nuclear β-Catenin was detected with anti-PY489 antibody (DSHB). For western blotting, lysates from day 3 CPCs after transfection with indicated siRNAs were analyzed using antibodies against Notch1 (DSHB), Dephospho β-Catenin (Calbiochem), and GAPDH (Santa Cruz Biotechnology).

Chromatin Immunoprecipitation Assays {#S6}
------------------------------------

For chromatin immunoprecipitation (ChIP) assay, EBs were treated with BIO (2.5 uM) or transfected with *Isl1* or *β-Catenin* constructs[@R22] (100 ng/ 10^5^ cells) from ED 5--7, and harvested at ED 8. Cross-linking of histones to DNA, chromatin extraction, immunoprecipitation and elution were performed using the ChIP Assay Kit (Upstate) with anti-IgG-HRP, Isl1 (Abcam) or β-Catenin (Santa Cruz Biotechnology). PCR primer sets spanning the indicated Lef/Tcf binding sites in the *Bhlhb2* locus are shown in [Supp. table 2](#SD4){ref-type="supplementary-material"}.

Supplementary Material {#SM}
======================

###### Supplementary figure 1

**a,** Relative *Isl1* expression levels in GFP^−^ and GFP^+^ cells isolated from Day 5 *Nkx2.5-GFP* EBs, determined by qPCR (mean ± s. d.; *n*=3). **b,** Immunostaining of transverse sections through the pre-cardiac mesoderm and outflow tract (ot) of indicated E 9.5 mouse embryos for nuclear β-Catenin. Higher levels of β-Catenin are observed in precardiac regions (arrowheads) in Notch1 mutants. Numerous Wnts are expressed in the ectodermal cells and form a gradient pattern of active β-Catenin (arrows), providing a positive control. **c,** qPCR data of positively affected genes in cardiac progenitors with stabilized β-Catenin (mean ± s. d.; *n*=3; \**P*\< 0.01). **d,** Transverse sections of corresponding embryos ([Fig. 2-l](#F2){ref-type="fig"}), focused on precardiac mesoderm (asterisk) and outflow tract (ot) area. h, heart. **e,** Relative *Bhlhb2* expression levels in hearts and precardiac mesoderm from E10.0 control or *Isl1^Cre^*; *Notch1^flox/flox^* embryos (Notch KO), determined by qPCR (mean ± s. d.; *n*=3; \**P* \< 0.01). **f,** Relative *Isl1* expression levels in EBs 2 days after transfection with an *Isl1 siRNA* constuct (transient *Isl1-KD*, left) and in ED6 EBs differentiated from control and stable *Isl1-KD* lines (stable *Isl1-KD*, right), determined by qPCR (mean ± s. d.; *n*=3; \**P* \< 0.01), Scale bars, 100 µm.

###### Supplementary figure 2

**a,** Histograms showing percentages of GFP^+^ cells of ED6, 7, and 8 EBs after transient transfection with an *Isl1 siRNA* construct on ED3. **b,** Histograms showing percentages of GFP^+^ cells of ED6 EBs differentiated from control and stable *Isl1-KD* lines.

###### Supplementary figure 3

**a,** Relative *Isl1* expression levels in EBs at indicated days of differentiation (ED), determined by qPCR. **b,** Histograms showing percentages of Myh7^+^ cells entering myocardial-lineage in ED9 EBs.
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![Notch1 loss-of-function causes CPC expansion and increases free β-Catenin levels. **a--f,** Control embryos. **g--l,** *Isl1^Cre^, Notch1^flox/flox^* embryos (N1-KO). **a**,**g**, Lateral views of ED10.5 embryos. **b, c, h, i,** Lateral (**b**,**h**) or frontal (**c**,**i**) view of embryos focused on cardiac regions showing absence of right ventricle (rv) in mutants. **d**,**e**, **j**, **k**, Transverse sections (H&E) of embryos (**d, j**) with enlargement of boxed areas (**e, k**) showing hyperplasia of precardiac progenitors (asterisk). **f**, **l,** Phosphohistone3 (Ph3, red) and Isl1 (green) immunostaining of transverse sections through the precardiac region. To compensate for the severe downregulation of Isl1 in Notch1 mutant embryos, Isl1 signals were amplified with the TSA system. DAPI (blue) was used to counterstain the nuclei. **m**, Percentage of ph3-positive cells in precardiac mesoderm region shown in **e** and **k** (mean ± s. d.; *n*=4; \**P* \< 0.01). **n**, Western analyses of FACS-purified CPCs transfected with *control siRNA* (C) or *Notch1 siRNA* (N1-KD) using Notch1, free or total β-Catenin antibodies. Free β-Catenin antibodies detect dephosphorylated β-Catenin, the effector molecule of the Wnt/β-Catenin signaling pathway. GAPDH antibody was used as a control. **o,** Relative number of cells on the 2^nd^ day after transfecting CPCs with *control* or *Notch1 siRNA* (mean ± s. d.; *n*=6; \**P* \< 0.01). **p,** Top/Fop flash activity in CPCs transfected with indicated *siRNA*. Top flash is a luciferase reporter with Tcf binding sites to read Wnt/β-Catenin signaling activity. Fop flash contains mutated Tcf binding sites. Luciferase values were normalized to Renilla activity (mean ± s. d.; *n*=3; \**P* \< 0.01). h, heart; pa, pharyngeal arch; ot, outflow tract; lv, left ventricle. Scale bars, 250 µm (**a, g**) or 100 µm (**b--e, h--k**).](nihms112298f1){#F1}

![Identification of genes affected by stabilized β-Catenin in cardiac progenitors. **a,** Lateral view of *Rosa^YFP^; Isl1^Cre^; β-catenin(ex3)^loxP^* embryo at E9.0 showing YFP^+^ cells in precardiac mesoderm (pm). **b,** Histograms of YFP^+^ cell populations from control (*Isl1^Cre^*, left) and stabilized β-cat (*Isl1^Cre^; β-catenin(ex3)^loxP^*, right) embryos. **c,** A heatmap of expression arrays showing significantly downregulated cardiac genes (green) in stabilized β-catenin pm cells. Color bar indicates fold change in log~2~ scale. **d,** qPCR data of downregulated genes in FACS-purified cardiac progenitors with stabilized β-Catenin (Top). These genes were similarly affected in pm of Notch1 loss-of-function embryos (Bottom). Data are mean ± s. d.; *n*=3; \**P* \< 0.01. **l,** Whole-mount in situ hybridization of genes indicated from control (top) and stabilized β-Catenin (bottom) embryos at E 9.5. Asterisks indicate precardiac mesoderm. h, heart. Scale bars, 100 µm.](nihms112298f2){#F2}

![*Isl1* loss-of-function results in expansion of CPCs and suppression of their myocardial and smooth muscle lineages.**a,** *YFP* expression in control (*Rosa^YFP^, Isl1^Cre/+^*, left) and *Isl1-null* (*Rosa^YFP^, Isl1^Cre/Cre^*, right) embryos at the 5-somite stage. Arrows indicate YFP^+^ CPCs. Scale bars, 50 µm. **b,** Quantification of YFP^+^ cells in indicated embryos at somite 5 (mean ± s. d.; *n*=3; \**P* \< 0.01). **c,** Quantification of GFP^+^ cells in ED6 *Nkx2.5-GFP* EBs with or without *Isl1 KD* (mean ± s. d.; *n*=3; \**P* \< 0.01). **d,** Relative number of cells on the 2^nd^ day after transfecting EB-derived CPCs with *lacZ*, *β-catenin*, or *Isl1* (mean ± s. d.; *n*=6; \**P* \< 0.01). **e,** Relative mRNA expression of indicated genes in control or *Isl1-KD* EBs at ED 9, determined by qPCR (mean ± s. d.; *n*=4; \**P* \< 0.01). **f,** Number of beating foci per 10[@R5] cells in control or *Isl1-KD* EBs at ED12. **g,** Schematic diagram of isolating CPCs from ES cells and their differentiation. **h,** Relative mRNA expression of endothelial (*Flk1, CD31*), cardiomyocyte (*Myh7, Mlc2v*) or smooth muscle (*Sma, Sm-mhc*) genes during CPC differentiation, determined by qPCR (mean ± s. e. m. ; *n*=4; \**P* \< 0.05).](nihms112298f3){#F3}

![Increased levels of *Isl1* promote myocardial differentiation. **a,** Schematic diagram of differentiation of *Myh7-GFP* ES cells with *Isl1* overexpression. **b, c,** Relative expression levels of *Isl1* on ED6 EBs (**b**), and endothelial (*Flk1*), cardiac sarcomeric (*Actc1, Mlc2v, Myh7*) and smooth muscle (*Sma*) genes on day 8 EBs (**c**), determined by qPCR. **d,** FACS analyses on ED 9 EBs to identify % of cells entering myocardial-lineage. Data are mean ± s. e. m.; *n*=3; \**P* \< 0.005.](nihms112298f4){#F4}

![Isl1 targets *Myocd* and β-Catenin regulates *Bhlhb2* to repress *Smyd1*. **a,** Relative expression levels of *Myocd* and *Smyd1* in FACS-purified control and *Isl1* knockdown (KD) CPCs, determined by qPCR (mean ± s. d.; *n*=4; \**P* \< 0.005). **b--i,** Control (**b--e**) and *Isl1-null* (**f--i**) embryos at E 9.5 after in situ hybridization with *Myocd* (**b--d**, **f--h**), or *Smyd1* (**e, i**) riboprobes. **c, g,** Lateral views focused on heart (h) and pharyngeal arch (pa) regions. **d, h,** Transverse section through the outfow tract. Asterisks indicate pre-cardiac mesoderm. Scale bars, 100 µm. **j,** Location of the conserved island containing Isl1 binding site (red) in the *Myocd* locus. **k**, Relative luciferase activity determined with luciferase reporters linked to the conserved island with the intact Isl1 site (Myocd-luc) or with a mutant Isl1 site (Myocd-luc^mt^) in the presence or absence of Isl1 (mean ± s. d.; *n*=3; \**P* \< 0.005). **l,** Chromatin immunoprecipitation (ChIP) assay shows specific PCR amplification of the Isl1 consensus site shown in **j**, representing association with Isl1 protein. **m,** Electophoretic mobility shift assay with in-vitro synthesized Isl1 protein and radiolabeled probes (Probe) spanning the Isl1 site shown in **j**. Unlabeled probes were used as competitors. WT, wildtype; MT, mutant. **n,** Relative expression levels of *Bhlhb2* in CPCs with stabilized β-Catenin, determined by qPCR (mean ±s. d.; *n*=3; \**P* \< 0.005).. **o,** Relative expression levels of *Smyd1* and *Isl1* after transfecting FACS-purified CPCs with *Bhlhb2* and differentiating them for 3 days (mean ± s. d.; *n*=3; \**P* \< 0.005). **p,** The *Bhlhb2* locus showing four conserved Lef/Tcf binding sites. **q,** ChIP assays performed with Lef/Tcf consensus sites shown in **p**. β-Catenin forms complexes with sites A and D as revealed by amplification of those sites. **r,** Relative luciferase activity determined with luciferase reporters containing the intact Lef/Tcf site D (Bhlhb2D-luc) or with a mutant Lef/Tcf site D (Bhlhb2D-luc^mt^) in the presence or absence of β-Catenin or BIO (2µM). Data are mean ± s. d.; *n*=3; \**P* \< 0.005. **s,** A molecular cascade involving Notch1/ β-Catenin/ Isl1 during CPC fate determination. Notch1 functions to negatively regulate accumulation of free β-Catenin, which regulates Myocd and Smyd1 through Isl1 and Bhlhb2, respectively, to determine CPC fates. Relationships indicated may be direct or indirect.](nihms112298f5){#F5}
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